<xmp id="sqcka"><progress id="sqcka"><bdo id="sqcka"></bdo></progress>
<xmp id="sqcka"><menuitem id="sqcka"></menuitem>
<progress id="sqcka"></progress>

    1. <bdo id="sqcka"></bdo>

      1. A POWERFUL RESEARCH AND
        DEVELOPMENT ENGINE

        Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

        • Phase 1 trials Phase 1 trials

          Phase 1 Trials

          CEMIPLIMAB*

          PD-1 Antibody Cancer

          REGN3767

          LAG-3 Antibody Cancer

          REGN1979

          CD20xCD3 Antibody Cancer

          REGN4018*

          MUC16xCD3 Antibody Cancer

          REGN4659

          CTLA4 Antibody Cancer
          REGN5093
          METxMET Antibody Cancer

          REGN5458*

          BCMAxCD3 Antibody Cancer
          REGN5459*
          BCMAxCD3 Antibody Cancer
          REGN5678
          PSMAxCD28 Antibody Cancer

          REGN3048-3051

          Middle East Respiratory Coronavirus Antibody MERS-CoV infection

          REGN4461

          LEPR Antibody Lipodystrophy and obesity
          REGN5713-5714-5715
          Betv1 Antibody Birch Allergy
        • Phase 2 trials Phase 2 trials

          Phase 2 Trials

          AFLIBERCEPT
          VEGF Trap High-dose for wet age-related macular degeneration (AMD)

          CEMIPLIMAB*

          PD-1 Antibody Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)
          REGN1979
          CD20xCD3 Antibody Relapsed/refractory follicular lymphoma

          DUPILUMAB*

          IL-4R Antibody Grass allergy, peanut allergy

          SARILUMAB*

          IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

          REGN1908-1909

          Fel d 1 Antibody Cat allergy

          REGN3500*

          IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis

          REGN5069

          GFRα3 Antibody Osteoarthritis knee pain

          GARETOSMAB

          Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)

          EVINACUMAB

          ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia

          POZELIMAB

          C5 Antibody Paroxysmal nocturnal hemoglobinuria
        • Phase 3 trials Phase 3 trials

          Phase 3 Trials

          AFLIBERCEPT
          VEGF Trap Retinopathy of Prematurity (ROP)

          ALIROCUMAB*

          PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics

          CEMIPLIMAB*

          PD-1 Antibody Non-small cell lung cancer (NSCLC), cervical cancer, cutaneous squamous cell carcinoma (CSCC) (adjuvant)

          REGN-EB3

          Ebola Virus Antibody Ebola virus infection

          DUPILUMAB*

          IL-4R Antibody Atopic dermatitis in pediatrics, asthma in pediatric, eosinophilic esophagitis, COPD

          SARILUMAB*

          IL-6R Antibody Polymyalgia rheumatica, giant cell arteritis

          EVINACUMAB

          ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)

          FASINUMAB?

          NGF Antibody Chronic pain from osteoarthritis of the knee or hip
        • IMMUNOLOGY & INFLAMMATORY DISEASES
        • ONCOLOGY
        • OPHTHALMOLOGY
        • RARE DISEASES
        • CARDIOVASCULAR/METABOLIC DISEASES
        • INFECTIOUS DISEASES
        • PAIN

        Trials Footnotes

        * in collaboration with Sanofi

        ? in collaboration with Teva and Mitsubishi Tanabe

        This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

        亚洲自拍偷拍